Icon Bioscience
Sunnyvale, US · Delaware corporation · 1 known investors
Find your way into Icon Bioscience
Icon Bioscience develops biodegradable, sustained-release intraocular ophthalmic products using its proprietary Verisome drug delivery technology, targeting unmet needs in inflammation, glaucoma, and retinal disease treatment.
Founders & leadership
DT
David TierneyinExecutive
Board
JE
ST
Song TojaBoard director
WW
William WhiteBoard director
MH
Michael HemricBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$5.3M disclosed across 1 round · 2015
▶$5.3MraisedDec 2015 · 18 investors · PharmaceuticalsRule 506(b)
▶$5.3MraisedDec 2015 · 18 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joyce EronyDirector
- David TierneyExecutive Officer, Director
- Song TojaDirector
- William WhiteDirector
- Michael HemricDirector
- Offering amount
- $9.8M
- Amount sold
- $5.3M
- First sale
- Nov 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap1Mg14 shared keywordsThis is a product listing page on an online pharmacy for Tugain Twins 5 Solution, a topical minoxidil-based medicine sold to treat hair loss and promote hair regrowth. The page provides usage instructions, benefits, side effects, and purchase/return details rather than describing a company.
Medscape12 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
Companies competing with Icon Bioscience for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Icon Bioscience do?
- Icon Bioscience develops biodegradable, sustained-release intraocular ophthalmic products using its proprietary Verisome drug delivery technology, targeting unmet needs in inflammation, glaucoma, and retinal disease treatment.
- Who are Icon Bioscience's investors?
- Icon Bioscience's investors include Signet Healthcare Partners.
- How much funding has Icon Bioscience raised?
- Icon Bioscience has disclosed $5.3M raised across 1 round.
- Where is Icon Bioscience headquartered?
- Icon Bioscience is headquartered in Sunnyvale, US.